Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.29
Bid: 6.52
Ask: 7.48
Change: 0.00 (0.00%)
Spread: 0.96 (14.724%)
Open: 7.29
High: 0.00
Low: 0.00
Prev. Close: 7.29
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding and Additional Listing

20 Oct 2008 07:00

RNS Number : 1671G
Synairgen plc
20 October 2008
 



20 October 2008

Director dealings

Synairgen plc ("Synairgen" or the "Company") was notified on 17 October that on the same day John Ward, Finance Director, acquired 22,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at 22 pence per share, equating to 0.01 per cent of the Company's issued Ordinary Share capital. Following this acquisition, Mr Ward has a beneficial interest of 44,692 Ordinary Shares, equating to 0.21 per cent of the Company's issued Ordinary Share capital. 

The Company was also notified on 17 October that on the same day Simon Shaw, non-executive chairman, exercised 700,000 of his Founder Options at nominal value. Following this exercise, Mr Shaw has a beneficial interest of 805,400 Ordinary Shares, equating to 3.71 per cent of the Company's issued share capital.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 700,000 Ordinary Shares (the "New Ordinary Shares"). The New Ordinary Shares are being admitted pursuant to the exercise of options under the Synairgen Chairman's 2004 New Share Option Agreement. It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 24 October 2008.

For further information:

Synairgen plc

John Ward

+44 2380 512800

Teathers Limited

Shaun Dobson/Claes Spang

+44 20 7426 9000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFKOKNABDDOKD
Date   Source Headline
28th Jun 20187:00 amRNSPositive SNG001 Biomarker Data in COPD Patients
26th Jun 20181:05 pmRNSHolding(s) in Company
22nd Jun 201811:42 amRNSResult of AGM
22nd Jun 20187:00 amRNSSynairgen Safety Data with SNG001 in COPD Patients
17th May 20187:00 amRNSPosting of Annual Report and Notice of AGM
16th Apr 20184:29 pmRNSHolding(s) in Company
6th Apr 201812:14 pmRNSGrant of Options
3rd Apr 20185:21 pmRNSHolding(s) in Company
15th Mar 20183:13 pmRNSIssue of Equity
15th Mar 20183:11 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSPreliminary results for year ended 31 Dec 2017
7th Feb 20187:00 amRNSSynairgen starts dosing in Phase II COPD study
14th Dec 20177:00 amRNSUpdate on LOXL2 Programme&Pharmaxis Collaboration
8th Nov 20174:31 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
27th Sep 20177:00 amRNSData update and clinical plan for COPD
13th Sep 201712:44 pmRNSHolding(s) in Company
6th Sep 20177:00 amRNSLOXL2 Inhibitor Update.
28th Jun 201712:41 pmRNSResult of AGM
5th Jun 20177:00 amRNSPosting of Annual Report and Notice of AGM
17th May 20177:00 amRNSPreliminary Results
27th Apr 20177:00 amRNSAZD9412 Update
27th Mar 20177:00 amRNSHolding(s) in Company
13th Mar 20173:10 pmRNSHolding(s) in Company
10th Mar 20178:34 amRNSAdditional Positive Data in Lung Fibrosis
17th Jan 20172:46 pmRNSHolding(s) in Company
13th Oct 201610:44 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSAZD9412 Clinical Trial Update
22nd Sep 20167:00 amRNSInterim results for six months ended 30 June 2016
8th Sep 20167:00 amRNSNotice of Interim Results
14th Jun 201612:00 pmRNSResult of AGM
17th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Apr 20162:14 pmRNSHolding(s) in Company
23rd Mar 20167:00 amRNSExercise of Options
22nd Mar 20167:00 amRNSPreliminary results for the year ended 31 Dec 2015
22nd Mar 20167:00 amRNSPositive LOXL2 results
3rd Mar 20167:00 amRNSNotice of Preliminary Results
16th Nov 20154:11 pmRNSAdoption of FRS 101 - Reduced Disclosure Framework
13th Nov 20153:08 pmRNSHolding(s) in Company
13th Nov 201511:41 amRNSHolding(s) in Company
13th Nov 20157:00 amRNSHolding(s) in Company
12th Nov 20157:00 amRNSDirectors' Share Purchase
28th Oct 20157:00 amRNSGrant of options
16th Sep 20157:00 amRNSInterim Results
21st Aug 20157:00 amRNSNotice of Interim Results
5th Aug 20157:00 amRNSSynairgen announces research collaboration
22nd Jul 20157:00 amRNSAstraZeneca commences Phase II Trial
22nd Jun 20151:41 pmRNSResult of AGM
2nd Jun 20159:37 amRNSHolding(s) in Company
15th May 201511:04 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.